Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.81 |
| ▸ | HTT | P42858 | 8/20 | 0.72 |
| ▸ | HPGD | P15428 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | TSHR | P16473 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224988 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL15503862 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20887162 | 0.82 | KDM4E (0.88) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20887260 | 0.81 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20886910 | 0.81 | KDM4E (0.86) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20887161 | 0.81 | KDM4E (0.85) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL2581454 | 0.79 | KDM4E (0.69) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20886904 | 0.79 | KDM4E (0.81) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20887160 | 0.78 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10HTTHPGD | |
| SCHEMBL20887035 | 0.78 | KDM4E (0.71) | KDM4EALDH1A1HSD17B10HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| JP-4656838-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | claimed |
| JP-2005526028-A | — | — | 2005-09-02 | — | — | JP | claimed |
| EP-1472245-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS, INCORPORATED | 2004-02-19 | — | — | US | claimed |
| WO-2003066629-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-14 | — | — | WO | claimed |
| EP-2322521-B1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2322521-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | Vertex Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| EP-1472245-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS, INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| WO-2003066629-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270420-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | KDM4E 1132/4885ALDH1A1 3514/4885HSD17B10 590/4885 |
| US-20040034037-A1 | Heteroaryl compounds useful as inhibitors of GSK-3 | GSK3B, GSK3A, GSKIP | KDM4E 1132/4885ALDH1A1 3514/4885HSD17B10 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.